Ionis Pharmaceuticals Shares Drop After Pelacarsen Fails Key Phase 3 Heart Trial
Ionis Pharmaceuticals (IONS) reported that Novartis' experimental drug pelacarsen did not meet its primary endpoint in the pivotal Phase 3 Lp(a)HORIZON trial. While the therapy effectively reduced levels of lipoprotein(a), or Lp(a)—a known risk factor for cardiovascular disease—it failed to demonstrate a reduction in major adverse cardiovascular events compared to placebo. The failure marks a setback for both Ionis and Novartis, as pelacarsen was seen as a potential blockbuster treatment targeting patients with elevated Lp(a) levels. The stock price of Ionis Pharmaceuticals dropped following the announcement due to investor concerns over the drug's future commercial viability in this indication. Despite not meeting its primary goal, some analysts suggest that further analysis may still reveal secondary benefits or subgroups where pelacarsen could be effective.
Topics: Cardiovascular Disease Drug Development Lp(a) Pharmaceuticals